Abstract:Background
Terminal complement pathway deficiencies often present with severe and recurrent infections. There is a lack of good-quality data on these rare conditions. This study investigated the clinical outcome and genetic variation in a large UK multi-center cohort with primary and secondary terminal complement deficiencies.
Methods
Clinicians from seven UK centers provided anonymised demographic, clinical, and laboratory data on patients with terminal c… Show more
Our understanding and management of atypical haemolytic uremic syndrome (HUS) has dramatically improved in the last decade. Atypical HUS has been established as a prototypic disease resulting from a dysregulation of the complement alternative C3 convertase. Subsequently, prospective non-randomized studies and retrospective series have shown the efficacy of C5 blockade in the treatment of this devastating disease. C5 blockade has become the cornerstone of the treatment of atypical HUS. This therapeutic breakthrough has been mitigated by persistent difficulties in the positive diagnosis of atypical HUS, and the latter remains, to date, a diagnosis by exclusion. Furthermore, the precise spectrum of complement-mediated renal thrombotic microangiopathy is still a matter of debate. Nevertheless, long-term management of atypical HUS is increasingly individualized and life-long C5 blockade is no more a paradigm that applies to all patients with this disease. The potential benefit of complement blockade in other forms of HUS, notably secondary HUS, remains uncertain.
Our understanding and management of atypical haemolytic uremic syndrome (HUS) has dramatically improved in the last decade. Atypical HUS has been established as a prototypic disease resulting from a dysregulation of the complement alternative C3 convertase. Subsequently, prospective non-randomized studies and retrospective series have shown the efficacy of C5 blockade in the treatment of this devastating disease. C5 blockade has become the cornerstone of the treatment of atypical HUS. This therapeutic breakthrough has been mitigated by persistent difficulties in the positive diagnosis of atypical HUS, and the latter remains, to date, a diagnosis by exclusion. Furthermore, the precise spectrum of complement-mediated renal thrombotic microangiopathy is still a matter of debate. Nevertheless, long-term management of atypical HUS is increasingly individualized and life-long C5 blockade is no more a paradigm that applies to all patients with this disease. The potential benefit of complement blockade in other forms of HUS, notably secondary HUS, remains uncertain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.